News

Cedar Grove Capital Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...
In its first quarter 2025 investor letter, Cedar Grove Capital Management emphasized stocks such as LENSAR, Inc. (NASDAQ:LNSR). LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company.
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser ...
The acquisition includes ALLY Robotic Cataract Laser Treatment Systemâ„¢, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond ...
March 24, 2025 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology ...
Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half of 2025. Perspective from John A. Hovanesian, MD, FACS Alcon will expand its ...
--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on ...